Quality of life: Endpoint score Quality of Well‐Being Scale index. Scale from: 0 to 10. · patients with chronic mental illnesses
1 finding from 1 review
Life skills: Endpoint score UCSD Performance‐based Skills Assessment ‐ UPSA · patients with chronic mental illnesses
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with chronic mental illnesses
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in sedation/tranquillisation: Not sedated ‐ at four hours compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in adverse effects: 1. Extrapyramidal side effects (TESS) compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in global state: 1. Requiring supplementary medication ‐ antipsychotics compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE may leads to lower global state: 2. Requiring 3 or more injections ‐ over 7 days compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in mental state: 1. No important improvement compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE showed no clear difference in adverse effects: Movement disorders ‐ dystonia (spasmodic postural… compared with STANDARD DRUG CARE (low certainty).
1 finding from 1 review
Sedation/tranquillisation: Not sedated ‐ at four hours · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 1. Requiring supplementary medication ‐ antipsychotics · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Global state: 2. Requiring 3 or more injections ‐ over 7 days · patients with acute schizophrenia and similar serious mental illnesses
1 finding from 1 review
Mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS score) · patients with acute schizophrenia and similar serious mental illnesses
ZUCLOPENTHIXOL ACETATE (HIGH DOSE) showed no clear difference in mental state: 1. Not markedly improved (BPRS, < 60% decrease in BPRS… compared with ZUCLOPENTHIXOL ACETATE (LOW DOSE) (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Quality of life · patients with schizophrenia
1 finding from 1 review
Adverse effects ‐ needing anticholinergic drugs · patients with schizophrenia
It is very uncertain whether bromperidol decanoate changes adverse effects ‐ needing anticholinergic drugs compared with other depot antipsychotic drugs (very low certainty).
1 finding from 1 review
Adverse effects ‐ anticholinergic effects · patients with schizophrenia
It is very uncertain whether bromperidol decanoate changes adverse effects ‐ anticholinergic effects compared with other depot antipsychotic drugs (very low certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders · patients with schizophrenia
It is very uncertain whether bromperidol decanoate changes adverse effects ‐ movement disorders compared with other depot antipsychotic drugs (very low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
1 finding from 1 review